3aya › Citations

Structural basis for distinct binding properties of the human galectins to Thomsen-Friedenreich antigen.

<div class='caption-title'>The distinct TF-binding specificities measured by ITC assay at 298 K.</div>
<div class='caption-title'>SPR analysis of the binding specificities for Gal-1, -3 CRD and mutants to immobilized GM1-biotin pentasaccharide at 298 K.</div>
<div class='caption-title'>Overall structures of Gal-3 CRD complexed with TF antigen and its derivatives.</div>
Bian CF, Zhang Y, Sun H, Li DF, Wang DC
OpenAccess logo PLoS One 6 e25007 (2011)
Related entries: 3ayc, 3ayd, 3aye

Cited: 46 times
EuropePMC logo PMID: 21949831

Abstract

The Thomsen-Friedenreich (TF or T) antigen, Galβ1-3GalNAcα1-O-Ser/Thr, is the core 1 structure of O-linked mucin type glycans appearing in tumor-associated glycosylation. The TF antigen occurs in about 90% of human cancer cells and is a potential ligand for the human endogenous galectins. It has been reported that human galectin-1 (Gal-1) and galectin-3 (Gal-3) can perform their cancer-related functions via specifically recognizing TF antigen. However, the detailed binding properties have not been clarified and structurally characterized. In this work, first we identified the distinct TF-binding abilities of Gal-1 and Gal-3. The affinity to TF antigen for Gal-3 is two orders of magnitude higher than that for Gal-1. The structures of Gal-3 carbohydrate recognition domain (CRD) complexed with TF antigen and derivatives, TFN and GM1, were then determined. These structures show a unique Glu-water-Arg-water motif-based mode as previously observed in the mushroom galectin AAL. The observation demonstrates that this recognition mode is commonly adopted by TF-binding galectins, either as endogenous or exogenous ones. The detailed structural comparisons between Gal-1 and Gal-3 CRD and mutagenesis experiments reveal that a pentad residue motif ((51)AHGDA(55)) at the loop (g1-L4) connecting β-strands 4 and 5 of Gal-1 produces a serious steric hindrance for TF binding. This motif is the main structural basis for Gal-1 with the low affinity to TF antigen. These findings provide the intrinsic structural elements for regulating the TF-binding activity of Gal-1 in some special conditions and also show certain target and approach for mediating some tumor-related bioactivities of human galectins.

Reviews - 3aya mentioned but not cited (1)

  1. Interaction of the Oncofetal Thomsen-Friedenreich Antigen with Galectins in Cancer Progression and Metastasis. Sindrewicz P, Lian LY, Yu LG. Front Oncol 6 79 (2016)

Articles - 3aya mentioned but not cited (2)

  1. Structural basis for distinct binding properties of the human galectins to Thomsen-Friedenreich antigen. Bian CF, Zhang Y, Sun H, Li DF, Wang DC. PLoS One 6 e25007 (2011)
  2. Thermodynamic Switch in Binding of Adhesion/Growth Regulatory Human Galectin-3 to Tumor-Associated TF Antigen (CD176) and MUC1 Glycopeptides. Rodriguez MC, Yegorova S, Pitteloud JP, Chavaroche AE, André S, Ardá A, Minond D, Jiménez-Barbero J, Gabius HJ, Cudic M. Biochemistry 54 4462-4474 (2015)


Reviews citing this publication (11)

  1. Role of protein glycosylation in cancer metastasis. Oliveira-Ferrer L, Legler K, Milde-Langosch K. Semin Cancer Biol 44 141-152 (2017)
  2. Tumor-associated antigens: Tn antigen, sTn antigen, and T antigen. Fu C, Zhao H, Wang Y, Cai H, Xiao Y, Zeng Y, Chen H. HLA 88 275-286 (2016)
  3. Galectin-3 as a Potential Target to Prevent Cancer Metastasis. Ahmed H, AlSadek DM. Clin Med Insights Oncol 9 113-121 (2015)
  4. Targeting Galectins With Glycomimetics. Bertuzzi S, Quintana JI, Ardá A, Gimeno A, Jiménez-Barbero J. Front Chem 8 593 (2020)
  5. Synthetic glycoconjugates inhibitors of tumor-related galectin-3: an update. Campo VL, Marchiori MF, Rodrigues LC, Dias-Baruffi M. Glycoconj J 33 853-876 (2016)
  6. Galectins and Ovarian Cancer. Shimada C, Xu R, Al-Alem L, Stasenko M, Spriggs DR, Rueda BR. Cancers (Basel) 12 E1421 (2020)
  7. Sialic acid as a target for the development of novel antiangiogenic strategies. Chiodelli P, Urbinati C, Paiardi G, Monti E, Rusnati M. Future Med Chem 10 2835-2854 (2018)
  8. CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a sweet success? Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. Front Med 16 322-338 (2022)
  9. Development of Galectin-3 Targeting Drugs for Therapeutic Applications in Various Diseases. Ahmed R, Anam K, Ahmed H. Int J Mol Sci 24 8116 (2023)
  10. Galectin-3 and Epithelial MUC1 Mucin-Interactions Supporting Cancer Development. Radziejewska I. Cancers (Basel) 15 2680 (2023)
  11. The universe of galectin-binding partners and their functions in health and disease. Troncoso MF, Elola MT, Blidner AG, Sarrias L, Espelt MV, Rabinovich GA. J Biol Chem 299 105400 (2023)

Articles citing this publication (32)

  1. Multiscale Simulations of Biological Membranes: The Challenge To Understand Biological Phenomena in a Living Substance. Enkavi G, Javanainen M, Kulig W, Róg T, Vattulainen I. Chem Rev 119 5607-5774 (2019)
  2. Aberrant glycosylation promotes lung cancer metastasis through adhesion to galectins in the metastatic niche. Reticker-Flynn NE, Bhatia SN. Cancer Discov 5 168-181 (2015)
  3. Galectin-3 interactions with glycosphingolipids. Collins PM, Bum-Erdene K, Yu X, Blanchard H. J Mol Biol 426 1439-1451 (2014)
  4. Stromal galectin-1 expression is associated with long-term survival in resectable pancreatic ductal adenocarcinoma. Chen R, Pan S, Ottenhof NA, de Wilde RF, Wolfgang CL, Lane Z, Post J, Bronner MP, Willmann JK, Maitra A, Brentnall TA. Cancer Biol Ther 13 899-907 (2012)
  5. Manifestations of immune tolerance in the human female reproductive tract. Clark GF, Schust DJ. Front Immunol 4 26 (2013)
  6. Binding of Galectin-3, a β-Galactoside-binding Lectin, to MUC1 Protein Enhances Phosphorylation of Extracellular Signal-regulated Kinase 1/2 (ERK1/2) and Akt, Promoting Tumor Cell Malignancy. Mori Y, Akita K, Yashiro M, Sawada T, Hirakawa K, Murata T, Nakada H. J Biol Chem 290 26125-26140 (2015)
  7. Low or No Inhibitory Potency of the Canonical Galectin Carbohydrate-binding Site by Pectins and Galactomannans. Stegmayr J, Lepur A, Kahl-Knutson B, Aguilar-Moncayo M, Klyosov AA, Field RA, Oredsson S, Nilsson UJ, Leffler H. J Biol Chem 291 13318-13334 (2016)
  8. Structural characterization of human galectin-4 C-terminal domain: elucidating the molecular basis for recognition of glycosphingolipids, sulfated saccharides and blood group antigens. Bum-Erdene K, Leffler H, Nilsson UJ, Blanchard H. FEBS J 282 3348-3367 (2015)
  9. Structural Basis Underlying the Binding Preference of Human Galectins-1, -3 and -7 for Galβ1-3/4GlcNAc. Hsieh TJ, Lin HY, Tu Z, Huang BS, Wu SC, Lin CH. PLoS One 10 e0125946 (2015)
  10. Identification of GlcNAcylated alpha-1-antichymotrypsin as an early biomarker in human non-small-cell lung cancer by quantitative proteomic analysis with two lectins. Jin Y, Wang J, Ye X, Su Y, Yu G, Yang Q, Liu W, Yu W, Cai J, Chen X, Liang Y, Chen Y, Wong BH, Fu X, Sun H. Br J Cancer 114 532-544 (2016)
  11. Galectin-3 Binds to Lubricin and Reinforces the Lubricating Boundary Layer of Articular Cartilage. Reesink HL, Bonnevie ED, Liu S, Shurer CR, Hollander MJ, Bonassar LJ, Nixon AJ. Sci Rep 6 25463 (2016)
  12. The water network in galectin-3 ligand binding site guides inhibitor design. Su J, Zhang T, Wang P, Liu F, Tai G, Zhou Y. Acta Biochim Biophys Sin (Shanghai) 47 192-198 (2015)
  13. Tumor-associated glycans and their role in gynecological cancers: accelerating translational research by novel high-throughput approaches. Pochechueva T, Jacob F, Fedier A, Heinzelmann-Schwarz V. Metabolites 2 913-939 (2012)
  14. Molecular basis for intestinal mucin recognition by galectin-3 and C-type lectins. Leclaire C, Lecointe K, Gunning PA, Tribolo S, Kavanaugh DW, Wittmann A, Latousakis D, MacKenzie DA, Kawasaki N, Juge N. FASEB J 32 3301-3320 (2018)
  15. Influence of protein (human galectin-3) design on aspects of lectin activity. García Caballero G, Beckwith D, Shilova NV, Gabba A, Kutzner TJ, Ludwig AK, Manning JC, Kaltner H, Sinowatz F, Cudic M, Bovin NV, Murphy PV, Gabius HJ. Histochem Cell Biol 154 135-153 (2020)
  16. Molecular Recognition of a Thomsen-Friedenreich Antigen Mimetic Targeting Human Galectin-3. Santarsia S, Grosso AS, Trovão F, Jiménez-Barbero J, Carvalho AL, Nativi C, Marcelo F. ChemMedChem 13 2030-2036 (2018)
  17. Development of an AlphaScreen assay for discovery of inhibitors of low-affinity glycan-lectin interactions. Yegorova S, Chavaroche AE, Rodriguez MC, Minond D, Cudic M. Anal Biochem 439 123-131 (2013)
  18. Red blood cell Thomsen-Friedenreich antigen expression and galectin-3 plasma concentrations in Streptococcus pneumoniae-associated hemolytic uremic syndrome and hemolytic anemia. Burin des Roziers N, Chadebech P, Bodivit G, Guinchard E, Bruneel A, Dupré T, Chevret L, Jugie M, Gallon P, Bierling P, Noizat-Pirenne F. Transfusion 55 1563-1571 (2015)
  19. Complement Factor H and Simian Virus 40 bind the GM1 ganglioside in distinct conformations. Blaum BS, Frank M, Walker RC, Neu U, Stehle T. Glycobiology 26 532-539 (2016)
  20. Chicken GRIFIN: Structural characterization in crystals and in solution. Ruiz FM, Gilles U, Ludwig AK, Sehad C, Shiao TC, García Caballero G, Kaltner H, Lindner I, Roy R, Reusch D, Romero A, Gabius HJ. Biochimie 146 127-138 (2018)
  21. Synthesis of the Thomsen-Friedenreich-antigen (TF-antigen) and binding of Galectin-3 to TF-antigen presenting neo-glycoproteins. Hoffmann M, Hayes MR, Pietruszka J, Elling L. Glycoconj J 37 457-470 (2020)
  22. Accurate Backbone 13 C and 15 N Chemical Shift Tensors in Galectin-3 Determined by MAS NMR and QM/MM: Details of Structure and Environment Matter. Kraus J, Gupta R, Lu M, Gronenborn AM, Akke M, Polenova T. Chemphyschem 21 1436-1443 (2020)
  23. Chemical Shifts of the Carbohydrate Binding Domain of Galectin-3 from Magic Angle Spinning NMR and Hybrid Quantum Mechanics/Molecular Mechanics Calculations. Kraus J, Gupta R, Yehl J, Lu M, Case DA, Gronenborn AM, Akke M, Polenova T. J Phys Chem B 122 2931-2939 (2018)
  24. Oligosaccharide Presentation Modulates the Molecular Recognition of Glycolipids by Galectins on Membrane Surfaces. Lete MG, Franconetti A, Delgado S, Jiménez-Barbero J, Ardá A. Pharmaceuticals (Basel) 15 145 (2022)
  25. TF-containing MUC1 glycopeptides fail to entice Galectin-1 recognition of tumor-associated Thomsen-Freidenreich (TF) antigen (CD176) in solution. FitzGerald FG, Rodriguez Benavente MC, Garcia C, Rivero Y, Singh Y, Wang H, Fields GB, Cudic M. Glycoconj J 37 657-666 (2020)
  26. Synthesis of branched and linear 1,4-linked galactan oligosaccharides. Andersen MCF, Boos I, Kinnaert C, Awan SI, Pedersen HL, Kračun SK, Lanz G, Rydahl MG, Kjærulff L, Håkansson M, Kimbung R, Logan DT, Gotfredsen CH, Willats WGT, Clausen MH. Org Biomol Chem 16 1157-1162 (2018)
  27. Structure of Galectin-3 bound to a model membrane containing ganglioside GM1. Vander Zanden CM, Majewski J, Weissbarth Y, Browne DF, Watkins EB, Gabius HJ. Biophys J 122 1926-1937 (2023)
  28. Synthesis of tricyclic carbohydrate-benzene hybrids as selective inhibitors of galectin-1 and galectin-8 N-terminal domains. Wu C, Yong C, Zhong Q, Wang Z, Nilsson UJ, Zhang Y. RSC Adv 10 19636-19642 (2020)
  29. The structure of SeviL, a GM1b/asialo-GM1 binding R-type lectin from the mussel Mytilisepta virgata. Kamata K, Mizutani K, Takahashi K, Marchetti R, Silipo A, Addy C, Park SY, Fujii Y, Fujita H, Konuma T, Ikegami T, Ozeki Y, Tame JRH. Sci Rep 10 22102 (2020)
  30. 3'-Sulfo-TF Antigen Determined by GAL3ST2/ST3GAL1 Is Essential for Antitumor Activity of Fungal Galectin AAL/AAGL. Li Y, Li Y, Xia J, Yang Q, Chen Y, Sun H. ACS Omega 6 17379-17390 (2021)
  31. Diagnosis of Malignant Potential in Mucinous Peritoneal Neoplasms by Characterization of Mucin Carbohydrate Structure. Clark LA, Ghazi A, Gaffney K, Soto R, Agarwal A, Carmack S, Boland CR. Cell Mol Gastroenterol Hepatol 6 108-109.e2 (2018)
  32. Oligosaccharide Ligands of Galectin-4 and Its Subunits: Multivalency Scores Highly. Slámová K, Červený J, Mészáros Z, Friede T, Vrbata D, Křen V, Bojarová P. Molecules 28 4039 (2023)


Quick links